GRAIL, LLC (GRAL)

GRAIL, LLC (GRAL) is a Diagnostics & Research company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $5.9B; returns 1 day +4.3%, 1 week +12.5%, 1 year +60.4%.

GRAIL, Inc. is a pioneer in the multi-cancer early detection (MCED) industry, having recently completed its spin-off from Illumina as an independent public entity. The company’s core economic driver is the Galleri test, a liquid biopsy capable of detecting more than 50 types of cancer through a single blood draw by identifying methylation patterns in cell-free DNA (cfDNA).

Groups GRAL belongs to

• Early Cancer Detection
• Oncology
• Healthcare
• Biotechnology
• Life Sciences
• Medical Devices
• Health Diagnostics and Imaging
• Precision Medicine
• Commercial Stage
• Preventive Care
• Healthcare Technology

GRAL financial model: income statement, cash flow and balance sheet